GSK's Mon­cef Slaoui joins the board at Mod­er­na; Aduro pro­motes van El­sas to CSO

→  Anap­tys­Bio CSO Matthew Moyle has abrupt­ly re­signed and left the com­pa­ny. An SEC fil­ing notes he got nine months salary as sev­er­ance.

→ An­drea van El­sas, the chief sci­en­tif­ic of­fi­cer of Aduro Biotech Eu­rope, will be ap­point­ed chief sci­en­tif­ic of­fi­cer of the moth­er com­pa­ny Aduro Biotech in Berkley, CA.

→ Mon­cef Slaoui, the for­mer R&D and vac­cines chief at Glax­o­SmithK­line, is join­ing the board at the mR­NA com­pa­ny Mod­er­na. Slaoui is an en­thu­si­as­tic cham­pi­on of pi­o­neer­ing drug R&D. And he says he’s look­ing “for­ward to work­ing with the team to nav­i­gate this un­chart­ed ter­ri­to­ry, and sup­port the strate­gic plan­ning al­ready un­der­way as Mod­er­na works to de­liv­er mR­NA med­i­cines and vac­cines to ad­dress se­ri­ous un­met med­ical needs in the U.S. and glob­al­ly.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER